Overall, more than 950,000 clinicians submitted queries to a popular AI platform from January 2024 to June 2026. Cardiovascular care was a common topic, especially questions about specific treatments and medications.
Cardiologists appear to be thriving in the face of adversity. Even as the specialty juggles an aging population, a workforce shortage and unfavorable reimbursement policies, compensation and productivity continue to climb.
FEVAR and BEVAR transformed how complex aortic aneurysms are treated. Clinicians now have an FDA-approved bridging stent option specifically indicated for these procedures.
One of the world's most well-known publications just dropped a new list of 300 different inventions. Cardiologists and other cardiology professionals may recognize a few entries.
Certain lots of argatroban, a blood thinner often used as an alternative to heparin during PCI, have been recalled due to the presence of particulate matter. The affected products should not be used to treat any patients due to an increased risk of adverse events.
The rise of CCTA continues to be one of modern medicine's biggest stories. An upcoming webinar will explore what cardiologists, executives and other stakeholders need to know about building and growing a productive CCTA program in 2026 and beyond.
Traditionally, the interventional cardiologist first visualizes the coronary anatomy in detail when contrast is injected in the catheterization laboratory. For many patients, however, that anatomy has already been captured, often in considerable detail, by coronary CT angiography (CCTA) performed earlier in the clinical pathway. This article considers how this dataset can be used to plan the procedure, an approach referred to as CT-guided PCI.
